Naphazoline
Based on 1 publication(s) in Google Scholar
Naphazoline (Naphthazoline) is a potent α-adrenergic receptor agonist. Naphazoline reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline can be used for non-bacterial conjunctivitis research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.74%
- CAS 番号: 835-31-4
- 分子式: C14H14N2
- 分子量:210.27
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
Neuronal Signaling Compound Library
HY-L013
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Antibacterial Compound Library
HY-L049
-
Pyroptosis Compound Library
HY-L059
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Protection Compound Library
HY-L144
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Cytokine Inhibitors Library
HY-L161
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
FDA Kinase Inhibitor Library
HY-L230
-
Lactylation Compound Library
HY-L249
MedChemExpress（MCE）の使用を引用している文献 Naphazoline
MoreAdrenergic Receptor アイソフォーム固有の製品をすべて表示
MoreVEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
|
IL-1β |
IL-6 |
IL-4 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female wild-type BALB/c mice (4-5 weeks, 18 ± 2 g, n=8/group, allergic conjunctivitis mouse model established using histamine or an antigen (ovalbumin))[1]
-
Dosage:0.2 mg/mL, 10 µl per eye
-
Administration:Intraperitoneal injection (IP), once
-
Result:Significantly suppressed conjunctival dye leakage in mice with histamine or antigen‑induced conjunctival vascular hyperpermeability. Reduced inflammatory reactions and the levels of IL-1β, IL-6, IFN-γ, and IL-4. Reduced the levels of IgE, GMCSF, NGF and VEGF in antigen-induced conjunctival vascular hyperpermeability mice.
化学情報
-
CAS 番号 835-31-4
-
性状 Solid
-
分子量 210.27
-
分子式 C14H14N2
-
Color White to light yellow
-
SMILES
C1(CC2=C3C=CC=CC3=CC=C2)=NCCN1
-
別名
Naphthazoline
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biomed Pharmacother
Identification of the atypical antipsychotic Asenapine as a direct survivin inhibitor with anticancer properties and sensitizing effects to conventional therapies. [Abstract]2025 Jan:182:117756. PMID: 39693907
溶剤 & 溶解度
DMSO : 62.5 mg/mL (297.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Quan L, et, al. Treatment with olopatadine and naphazoline hydrochloride reduces allergic conjunctivitis in mice through alterations in inflammation, NGF and VEGF. Mol Med Rep. 2016 Apr;13(4):3319-25. [Content Brief]
[2]. Yamaguchi I, et, al. Central and peripheral adrenergic mechanisms regulating gastric secretion in the rat. J Pharmacol Exp Ther. 1977 Oct;203(1):125-31. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.7558 mL | 23.7790 mL | 47.5579 mL | 118.8948 mL |
| 5 mM | 0.9512 mL | 4.7558 mL | 9.5116 mL | 23.7790 mL | |
| 10 mM | 0.4756 mL | 2.3779 mL | 4.7558 mL | 11.8895 mL | |
| 15 mM | 0.3171 mL | 1.5853 mL | 3.1705 mL | 7.9263 mL | |
| 20 mM | 0.2378 mL | 1.1889 mL | 2.3779 mL | 5.9447 mL | |
| 25 mM | 0.1902 mL | 0.9512 mL | 1.9023 mL | 4.7558 mL | |
| 30 mM | 0.1585 mL | 0.7926 mL | 1.5853 mL | 3.9632 mL | |
| 40 mM | 0.1189 mL | 0.5945 mL | 1.1889 mL | 2.9724 mL | |
| 50 mM | 0.0951 mL | 0.4756 mL | 0.9512 mL | 2.3779 mL | |
| 60 mM | 0.0793 mL | 0.3963 mL | 0.7926 mL | 1.9816 mL | |
| 80 mM | 0.0594 mL | 0.2972 mL | 0.5945 mL | 1.4862 mL | |
| 100 mM | 0.0476 mL | 0.2378 mL | 0.4756 mL | 1.1889 mL |
Naphazoline 関連分類
HY-111326 関連分類
Powered by Bioz